Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

RARITY

Financiado

RAtional design of canceR ImmunoTherapY one size does not fit all

Checkpoint blockade immunotherapies have revolutionized cancer treatment. However, this immunotherapy only benefits a minority of patients (< 15%), mainly those diagnosed with cancers having many mutations. Furthermore, checkpoint... ver más

30/11/2024

Leiden University...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-11-27

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2019-STG: ERC Starting Grant

I+D

Cerrada hace 6 años

0% 100% 100%

2 Participantes

Leiden University Medical Ce...

1.50M€ | Lider

TALLERES DAUMAR

Proyectos interesantes

EXPAND IT EXPANDing Immune Cells and their Tumor Antigens during check... 3M€ Cerrado

ImmunoChip Nano-assisted digitalizing of cancer phenotyping for immunot... 2M€ Cerrado

CAN-IT-BARRIERS Disruption of systemic and microenvironmental barriers to i... 3M€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

IOO - Improving IO IOO: a novel assay to predict patient response to immune che... 4M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 60 meses Fecha Inicio: 2019-11-27
Fecha Fin: 2024-11-30

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Checkpoint blockade immunotherapies have revolutionized cancer treatment. However, this immunotherapy only benefits a minority of patients (< 15%), mainly those diagnosed with cancers having many mutations. Furthermore, checkpoint blockade therapy does not selectively activate cancer-reactive T cells. RARITY responds to these shortcomings, aiming to provide innovative solutions for the development of effective immunotherapies for patients who do not benefit from current treatments. The ground-breaking preliminary data included in this application demonstrates that cancer-reactive T cells can be naturally present in so-called non-immunogenic cancers and that they acquire distinctive phenotypes. RARITY will apply state-of-the-art technologies to fingerprint these phenotypes. This will allow the isolation of cancer-reactive T cells from tumour tissues and their employment as highly-effective therapies. Therapeutic vaccination with cancer antigens can also be used to induce T cell responses in patients where natural activation of cancer-specific T cells is not detectable. However, the applicability of vaccination is compromised by the lack of specific targets, particularly in malignancies with few mutations. RARITY will address this problem by deploying a novel class of cancer antigens. An unprecedented screening of non-exomic genomic regions will be done to detect unannotated proteins that arise from de novo transcription and translation events. These proteins can then be targeted by personalized immunotherapies. Finally, thought-provoking findings included in RARITY suggest that immune cell subsets other than T cells play a major role in anti-tumour immune responses. These subsets need to be fully inventoried and categorised so that complementary strategies to T cell immunotherapies can be developed. RARITY will do so by conducting multidimensional analysis of cancer microenvironments using imaging mass cytometry and ex vivo modulation of immune responses.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores